BioStem files Form D for $3 million offering tied to September private placement
The regenerative medicine company disclosed a Form D exempt securities notice as its S-1 resale registration and going concern disclosures remain pending.
BioStem Technologies Inc. (Nasdaq: BSEM) filed a Form D notice of exempt offering with the SEC, reporting a total offering amount of $3,000,000, with the total amount sold also at $3,000,000 and nothing remaining to be sold1. The filing listed a date of first sale of September 29, 20261 and two investors who had already invested in the offering1. The company claimed exemption under Rule 506(b)1.
That offering matches the private placement BioStem announced on September 30, 2026, in which it said it entered into definitive agreements for the issuance and sale of 735,296 shares of common stock, Series A warrants to purchase up to an aggregate of 735,296 shares of common stock and Series B warrants to purchase up to an aggregate of 735,296 shares of common stock, at a purchase price of $4.08 per share and associated warrants in a private placement priced at-the-market under Nasdaq rules2. BioStem said the aggregate gross proceeds from the offering were expected to be approximately $3 million, before deducting placement agent fees and other offering expenses2.
The company's pending S-1, filed October 2, 2026, seeks to register resale of up to 2,224,270 shares tied to that same purchase agreement, and separately disclosed that BioStem has identified conditions that raise substantial doubt about its ability to continue as a going concern3.
Also unresolved is a payment tied to BioStem's BioTissue acquisition. Under the asset purchase agreement, BioStem is obligated to pay BioTissue $10.0 million upon BioTissue's receipt of 510(k) clearance of the Catalyze product, an FDA-cleared advanced wound care device3, and BioTissue received such clearance in June 2026, with the payment due by September 15, 2026 under an amendment3. As of the S-1 filing, BioStem said it remained in continued discussions with BioTissue over the payment, which had not yet been made, while it continues to seek debt and equity financing to fund it3.
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.